A combination of botanical extracts, phytonutrients, botanically enhanced medicinal mushrooms, and antioxidants has gone into preparing an all-natural, doctor-designed formula that shows promise to fight aggressive prostate cancer tumours, researchers say.
A xenograft model is when tissue or organs from an individual of one species are transplanted or grafted onto an organism of another species, genus, or family. So human prostate cancer cells (tissue) are grafted onto a laboratory animal, which in this case were mice.
Lead investigator, Dr. Daniel Sliva presented the results of this in vivo (live animal) study, demonstrating the significant effects of the formula in suppressing the proliferation and metastasis of human hormone refractory (androgen independent) prostate cancer cells.
In addition, the toxicology analysis proved that this formula is non-toxic and poses no risk of side effects.
"Dietary supplements are used as an alternative or adjuvant therapies. However, rigorous scientific verification of their biological activity in vitro and in vivo is necessary for the acceptance of dietary supplements in conventional cancer treatment and prevention," said Dr. Sliva.
This in vivo study is significant because hormone refractory prostate cancer (androgen independent) is especially hard to treat.
It's the more aggressive, advanced form of prostate cancer that often leads to metastasis and progression of the cancer.
The ingredients were selected based on scientific research demonstrating their abilities to fight prostate abnormalities and provide broad-spectrum prostate support.
Results of the study showed that the oral administration of this formula produced a statistically significant suppression of tumour growth, compared to controls.
In addition to a significant reduction in tumour volume, results of this study showed the formula also worked to inhibit a number of genes involved in cancer proliferation and metastasis.
"In summary, this dietary supplement is a natural compound for the possible therapy of human hormone refractory (independent) prostate cancer," added Dr. Sliva.